Testing two doses of a new lung scarring treatment

Plain-English translation of NCT07516951 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated September 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called zampilimab to see if it can help people with idiopathic pulmonary fibrosis (IPF)—a serious condition where the lungs become increasingly scarred and stiff over time. Researchers want to find the best dose of this medication and learn whether it is safe and effective. About 240 people will participate across multiple countries.

Idiopathic pulmonary fibrosis is a progressive disease with limited treatment options, and people diagnosed with it face a difficult prognosis. This trial exists to determine whether this medication can slow disease progression and improve outcomes for people living with this condition.

Do you qualify?

You likely qualify if…

you are at least 40 years old and expected to live for at least 1 more year
you have been diagnosed with idiopathic pulmonary fibrosis within the past 8 years
your lung function tests show specific measurements (FVC ≥45% predicted and FEV1/FVC ≥0.7)
your oxygen levels at rest are above 90% (with or without supplemental oxygen up to 4 L/min)
you weigh at least 45 kilograms (about 99 pounds)
you can provide informed written consent to participate

You likely don't qualify if…

you have had a lung or respiratory tract infection in the past 4 weeks or a sudden worsening of your IPF symptoms
you have been diagnosed with or have a history of lung cancer
you are currently taking or have taken immunosuppressant or chemotherapy drugs within the past 12 months
you have severe emphysema (more than 20% of your lungs) that is greater in extent than your fibrosis
you have other serious uncontrolled medical conditions (heart, liver, kidney, or other pulmonary diseases) that would interfere with the study

What participation looks like

If you join this study, you will be randomly assigned to receive either one of two doses of the medication or a placebo (inactive treatment). You will visit the research center multiple times over 24 weeks so doctors can monitor your lung function, oxygen levels, and overall health. The study will involve breathing tests, blood work, and chest imaging to track whether the treatment is working and how well you are tolerating it.

AI-generated summary from trial data · Sep 5, 2026 · Not medical advice

Trial locations(19 sites)

United States

SEC Clinical Research LLC, Dothan, Alabama

Pasadena Center for Medical Research, Inc, St. Petersburg, Florida

Hannibal Regional Healthcare System, Inc., Hannibal, Missouri

Clinical Research of Rock Hill, Rock Hill, South Carolina

Tennessee Comprehensive Lung and Sleep Center, Hendersonville, Tennessee